SlideShare une entreprise Scribd logo
Turning the tide on
cancer drug costs
The increase in the median monthly cost
of cancer drugs in the US since 19902
©2015EYGMLimited.AllRightsReserved.EYGno.FN0236.EDNone
1 A rising tide of new cancer
drugs helps patients.
These contracts are complex to
build, but can provide a strong
foundation for patient access.
To hold back the tide of oncology drug costs, payers …3
... experiment with new models
US payers test indication-specific
pricing, taking advantage of
four new drug value tools.
Since 2006, NICE has issued negative
recommendations for
of the cancer
drugs reviewed.3
... limit patient access
Innovative risk-sharing agreements
are another way to turn the tide.4
of the contracts
are for cancer
drugs.4
65%The number of
risk-sharing contracts
created in the
UK and Italy since 2006
90
Sources: 1
U.S. Food & Drug Administration, Memorial Sloan Kettering Cancer Center, Decision Resources. 2
Peter Bach, Memorial Sloan Kettering Cancer Center,
Center for Health Policy and Outcomes, "Price and Value of Cancer Drug," 2015. 3
EY, National Institute for Health and Care Excellence (NICE).
4
Van de Vooren, et al., “Market-access agreements for anti-cancer drugs,” J R Soc Med (108): 166–170, 2015.
Since 1990,
new cancer drugs have
been approved in the US.
117
50Another
could reach the market by 2020.1
$41%
>700%
2 This wave of innovation
could drown payers.

Contenu connexe

Tendances

Prescription Medicines - Costs in Context - October 2018
Prescription Medicines - Costs in Context - October 2018Prescription Medicines - Costs in Context - October 2018
Prescription Medicines - Costs in Context - October 2018PhRMA
 
Opportunities and Barriers in Pharmaceutical Pricing: Average Manufacturer Pr...
Opportunities and Barriers in Pharmaceutical Pricing: Average Manufacturer Pr...Opportunities and Barriers in Pharmaceutical Pricing: Average Manufacturer Pr...
Opportunities and Barriers in Pharmaceutical Pricing: Average Manufacturer Pr...Epstein Becker Green
 
Webinar 1: Has the PMPRB removed the obstacles to access in its Guidelines?
Webinar 1: Has the PMPRB removed the obstacles to access in its Guidelines?Webinar 1: Has the PMPRB removed the obstacles to access in its Guidelines?
Webinar 1: Has the PMPRB removed the obstacles to access in its Guidelines?Canadian Organization for Rare Disorders
 
Biopharma Sales Resilience through Economic Recession
Biopharma Sales Resilience through Economic RecessionBiopharma Sales Resilience through Economic Recession
Biopharma Sales Resilience through Economic RecessionHealth Advances
 
Prescription Medicines Costs in Context October 2020
Prescription Medicines Costs in Context October 2020Prescription Medicines Costs in Context October 2020
Prescription Medicines Costs in Context October 2020PhRMA
 
3º FÓRUM DA SAÚDE SUPLEMENTAR - RACHEL DAVID
3º FÓRUM DA SAÚDE SUPLEMENTAR - RACHEL DAVID3º FÓRUM DA SAÚDE SUPLEMENTAR - RACHEL DAVID
3º FÓRUM DA SAÚDE SUPLEMENTAR - RACHEL DAVIDCNseg
 
Prescription Medicines Costs in Context April 2021
Prescription Medicines Costs in Context April 2021Prescription Medicines Costs in Context April 2021
Prescription Medicines Costs in Context April 2021PhRMA
 
SB 17 doesn't address most pressing issues for CA voters
SB 17 doesn't address most pressing issues for CA votersSB 17 doesn't address most pressing issues for CA voters
SB 17 doesn't address most pressing issues for CA votersPhRMA
 
3º FÓRUM DA SAÚDE SUPLEMENTAR - CARMELLA BOCCHINO
3º FÓRUM DA SAÚDE SUPLEMENTAR - CARMELLA BOCCHINO3º FÓRUM DA SAÚDE SUPLEMENTAR - CARMELLA BOCCHINO
3º FÓRUM DA SAÚDE SUPLEMENTAR - CARMELLA BOCCHINOCNseg
 
Prescription Medicines Costs in Context November 2019
Prescription Medicines Costs in Context November 2019Prescription Medicines Costs in Context November 2019
Prescription Medicines Costs in Context November 2019PhRMA
 
Prescription Medicines: Insulin Costs in Context January 2021
Prescription Medicines: Insulin Costs in Context January 2021Prescription Medicines: Insulin Costs in Context January 2021
Prescription Medicines: Insulin Costs in Context January 2021PhRMA
 
July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...
July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...
July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...Canadian Organization for Rare Disorders
 
Roadmap to Optimal Drug Access (Chris Bonnett, H3 Consulting) June 14, 2017
Roadmap to Optimal Drug Access (Chris Bonnett, H3 Consulting) June 14, 2017Roadmap to Optimal Drug Access (Chris Bonnett, H3 Consulting) June 14, 2017
Roadmap to Optimal Drug Access (Chris Bonnett, H3 Consulting) June 14, 2017Canadian Organization for Rare Disorders
 
Mercer Capital's Value Focus: Medical Technology | Mid-Year 2021
Mercer Capital's Value Focus: Medical Technology | Mid-Year 2021Mercer Capital's Value Focus: Medical Technology | Mid-Year 2021
Mercer Capital's Value Focus: Medical Technology | Mid-Year 2021Mercer Capital
 
Prescription Medicines Costs in Context July 2021
Prescription Medicines Costs in Context July 2021Prescription Medicines Costs in Context July 2021
Prescription Medicines Costs in Context July 2021PhRMA
 
Insight into the 2018 individual exchange market - PPT
Insight into the 2018 individual exchange market - PPTInsight into the 2018 individual exchange market - PPT
Insight into the 2018 individual exchange market - PPTMcKinsey on Healthcare
 
Prescription Medicines Costs in Context January 2020
Prescription Medicines Costs in Context January 2020Prescription Medicines Costs in Context January 2020
Prescription Medicines Costs in Context January 2020PhRMA
 
10 Essential Facts About Medicare and Prescription Drug Spending
10 Essential Facts About Medicare and Prescription Drug Spending10 Essential Facts About Medicare and Prescription Drug Spending
10 Essential Facts About Medicare and Prescription Drug SpendingKFF
 

Tendances (20)

Prescription Medicines - Costs in Context - October 2018
Prescription Medicines - Costs in Context - October 2018Prescription Medicines - Costs in Context - October 2018
Prescription Medicines - Costs in Context - October 2018
 
Opportunities and Barriers in Pharmaceutical Pricing: Average Manufacturer Pr...
Opportunities and Barriers in Pharmaceutical Pricing: Average Manufacturer Pr...Opportunities and Barriers in Pharmaceutical Pricing: Average Manufacturer Pr...
Opportunities and Barriers in Pharmaceutical Pricing: Average Manufacturer Pr...
 
Webinar 1: Has the PMPRB removed the obstacles to access in its Guidelines?
Webinar 1: Has the PMPRB removed the obstacles to access in its Guidelines?Webinar 1: Has the PMPRB removed the obstacles to access in its Guidelines?
Webinar 1: Has the PMPRB removed the obstacles to access in its Guidelines?
 
Biopharma Sales Resilience through Economic Recession
Biopharma Sales Resilience through Economic RecessionBiopharma Sales Resilience through Economic Recession
Biopharma Sales Resilience through Economic Recession
 
Roadmap to Optimal Drug Access (Neil Palmer, PDCI) June 14, 2017
Roadmap to Optimal Drug Access (Neil Palmer, PDCI) June 14, 2017Roadmap to Optimal Drug Access (Neil Palmer, PDCI) June 14, 2017
Roadmap to Optimal Drug Access (Neil Palmer, PDCI) June 14, 2017
 
Prescription Medicines Costs in Context October 2020
Prescription Medicines Costs in Context October 2020Prescription Medicines Costs in Context October 2020
Prescription Medicines Costs in Context October 2020
 
3º FÓRUM DA SAÚDE SUPLEMENTAR - RACHEL DAVID
3º FÓRUM DA SAÚDE SUPLEMENTAR - RACHEL DAVID3º FÓRUM DA SAÚDE SUPLEMENTAR - RACHEL DAVID
3º FÓRUM DA SAÚDE SUPLEMENTAR - RACHEL DAVID
 
Prescription Medicines Costs in Context April 2021
Prescription Medicines Costs in Context April 2021Prescription Medicines Costs in Context April 2021
Prescription Medicines Costs in Context April 2021
 
SB 17 doesn't address most pressing issues for CA voters
SB 17 doesn't address most pressing issues for CA votersSB 17 doesn't address most pressing issues for CA voters
SB 17 doesn't address most pressing issues for CA voters
 
3º FÓRUM DA SAÚDE SUPLEMENTAR - CARMELLA BOCCHINO
3º FÓRUM DA SAÚDE SUPLEMENTAR - CARMELLA BOCCHINO3º FÓRUM DA SAÚDE SUPLEMENTAR - CARMELLA BOCCHINO
3º FÓRUM DA SAÚDE SUPLEMENTAR - CARMELLA BOCCHINO
 
Prescription Medicines Costs in Context November 2019
Prescription Medicines Costs in Context November 2019Prescription Medicines Costs in Context November 2019
Prescription Medicines Costs in Context November 2019
 
Prescription Medicines: Insulin Costs in Context January 2021
Prescription Medicines: Insulin Costs in Context January 2021Prescription Medicines: Insulin Costs in Context January 2021
Prescription Medicines: Insulin Costs in Context January 2021
 
July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...
July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...
July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...
 
Roadmap to Optimal Drug Access (Chris Bonnett, H3 Consulting) June 14, 2017
Roadmap to Optimal Drug Access (Chris Bonnett, H3 Consulting) June 14, 2017Roadmap to Optimal Drug Access (Chris Bonnett, H3 Consulting) June 14, 2017
Roadmap to Optimal Drug Access (Chris Bonnett, H3 Consulting) June 14, 2017
 
Mercer Capital's Value Focus: Medical Technology | Mid-Year 2021
Mercer Capital's Value Focus: Medical Technology | Mid-Year 2021Mercer Capital's Value Focus: Medical Technology | Mid-Year 2021
Mercer Capital's Value Focus: Medical Technology | Mid-Year 2021
 
Roadmap to Optimal Drug Access (Vivian Leong MOHLTC) June 14, 2017
Roadmap to Optimal Drug Access (Vivian Leong MOHLTC) June 14, 2017Roadmap to Optimal Drug Access (Vivian Leong MOHLTC) June 14, 2017
Roadmap to Optimal Drug Access (Vivian Leong MOHLTC) June 14, 2017
 
Prescription Medicines Costs in Context July 2021
Prescription Medicines Costs in Context July 2021Prescription Medicines Costs in Context July 2021
Prescription Medicines Costs in Context July 2021
 
Insight into the 2018 individual exchange market - PPT
Insight into the 2018 individual exchange market - PPTInsight into the 2018 individual exchange market - PPT
Insight into the 2018 individual exchange market - PPT
 
Prescription Medicines Costs in Context January 2020
Prescription Medicines Costs in Context January 2020Prescription Medicines Costs in Context January 2020
Prescription Medicines Costs in Context January 2020
 
10 Essential Facts About Medicare and Prescription Drug Spending
10 Essential Facts About Medicare and Prescription Drug Spending10 Essential Facts About Medicare and Prescription Drug Spending
10 Essential Facts About Medicare and Prescription Drug Spending
 

En vedette

How do we see the healthcare's digital future and its impact on our lives?
How do we see the healthcare's digital future and its impact on our lives?How do we see the healthcare's digital future and its impact on our lives?
How do we see the healthcare's digital future and its impact on our lives?Jane Vita
 
Prescription Medicines: Costs in Context
Prescription Medicines: Costs in Context Prescription Medicines: Costs in Context
Prescription Medicines: Costs in Context PhRMA
 
How Data Saves Time
How Data Saves TimeHow Data Saves Time
How Data Saves TimeNetApp
 
The Digital Prescription for Pharmacy Event - Digital Leadership for Pharmaci...
The Digital Prescription for Pharmacy Event - Digital Leadership for Pharmaci...The Digital Prescription for Pharmacy Event - Digital Leadership for Pharmaci...
The Digital Prescription for Pharmacy Event - Digital Leadership for Pharmaci...Doyle Buehler
 
3 Things Every Sales Team Needs to Be Thinking About in 2017
3 Things Every Sales Team Needs to Be Thinking About in 20173 Things Every Sales Team Needs to Be Thinking About in 2017
3 Things Every Sales Team Needs to Be Thinking About in 2017Drift
 
The Shifting Landscape of Healthcare in Asia-Pacific Japanese Infographic
The Shifting Landscape of Healthcare in Asia-Pacific Japanese InfographicThe Shifting Landscape of Healthcare in Asia-Pacific Japanese Infographic
The Shifting Landscape of Healthcare in Asia-Pacific Japanese InfographicThe Economist Media Businesses
 
The Future of Medical Education - Top Trends Likely to Have an Impact on the ...
The Future of Medical Education - Top Trends Likely to Have an Impact on the ...The Future of Medical Education - Top Trends Likely to Have an Impact on the ...
The Future of Medical Education - Top Trends Likely to Have an Impact on the ...Ogilvy Health
 
The Link Between Alcohol and Breast Cancer
The Link Between Alcohol and Breast CancerThe Link Between Alcohol and Breast Cancer
The Link Between Alcohol and Breast CancerDr. Omer Hameed
 
Six secrets-to-closing-sale
Six secrets-to-closing-saleSix secrets-to-closing-sale
Six secrets-to-closing-saleBenjamin Brown
 
How Real-time Analysis turns Big Medical Data into Precision Medicine
How Real-time Analysis turns Big Medical Data into Precision MedicineHow Real-time Analysis turns Big Medical Data into Precision Medicine
How Real-time Analysis turns Big Medical Data into Precision MedicineMatthieu Schapranow
 
Anaesthetic management of valvular heart disease for non cardiac surgery
Anaesthetic management of valvular heart disease for non cardiac surgeryAnaesthetic management of valvular heart disease for non cardiac surgery
Anaesthetic management of valvular heart disease for non cardiac surgeryNaveen Cheran
 
What Your Employees Don't Know About Healthcare [Infographic]
What Your Employees Don't Know About Healthcare [Infographic]What Your Employees Don't Know About Healthcare [Infographic]
What Your Employees Don't Know About Healthcare [Infographic]BambooHR
 
Elsevier Medical Graph – mit Machine Learning zu Precision Medicine
Elsevier Medical Graph – mit Machine Learning zu Precision MedicineElsevier Medical Graph – mit Machine Learning zu Precision Medicine
Elsevier Medical Graph – mit Machine Learning zu Precision MedicineRising Media Ltd.
 
How fit is your capital allocation strategy?
How fit is your capital allocation strategy? How fit is your capital allocation strategy?
How fit is your capital allocation strategy? EY
 
Genomic Medicine: Personalized Care for Just Pennies
Genomic Medicine: Personalized Care for Just PenniesGenomic Medicine: Personalized Care for Just Pennies
Genomic Medicine: Personalized Care for Just PenniesHealth Catalyst
 
C-Change Cancer Big Data, NCI Genomic Data Commons, Cloud Pilots
C-Change Cancer Big Data, NCI Genomic Data Commons, Cloud PilotsC-Change Cancer Big Data, NCI Genomic Data Commons, Cloud Pilots
C-Change Cancer Big Data, NCI Genomic Data Commons, Cloud PilotsWarren Kibbe
 
Precision Medicine: Opportunities and Challenges for Clinical Trials
Precision Medicine: Opportunities and Challenges for Clinical TrialsPrecision Medicine: Opportunities and Challenges for Clinical Trials
Precision Medicine: Opportunities and Challenges for Clinical TrialsMedpace
 

En vedette (19)

How do we see the healthcare's digital future and its impact on our lives?
How do we see the healthcare's digital future and its impact on our lives?How do we see the healthcare's digital future and its impact on our lives?
How do we see the healthcare's digital future and its impact on our lives?
 
Prescription Medicines: Costs in Context
Prescription Medicines: Costs in Context Prescription Medicines: Costs in Context
Prescription Medicines: Costs in Context
 
How Data Saves Time
How Data Saves TimeHow Data Saves Time
How Data Saves Time
 
The Digital Prescription for Pharmacy Event - Digital Leadership for Pharmaci...
The Digital Prescription for Pharmacy Event - Digital Leadership for Pharmaci...The Digital Prescription for Pharmacy Event - Digital Leadership for Pharmaci...
The Digital Prescription for Pharmacy Event - Digital Leadership for Pharmaci...
 
3 Things Every Sales Team Needs to Be Thinking About in 2017
3 Things Every Sales Team Needs to Be Thinking About in 20173 Things Every Sales Team Needs to Be Thinking About in 2017
3 Things Every Sales Team Needs to Be Thinking About in 2017
 
Healthcare
HealthcareHealthcare
Healthcare
 
The Shifting Landscape of Healthcare in Asia-Pacific Japanese Infographic
The Shifting Landscape of Healthcare in Asia-Pacific Japanese InfographicThe Shifting Landscape of Healthcare in Asia-Pacific Japanese Infographic
The Shifting Landscape of Healthcare in Asia-Pacific Japanese Infographic
 
The Future of Medical Education - Top Trends Likely to Have an Impact on the ...
The Future of Medical Education - Top Trends Likely to Have an Impact on the ...The Future of Medical Education - Top Trends Likely to Have an Impact on the ...
The Future of Medical Education - Top Trends Likely to Have an Impact on the ...
 
The Link Between Alcohol and Breast Cancer
The Link Between Alcohol and Breast CancerThe Link Between Alcohol and Breast Cancer
The Link Between Alcohol and Breast Cancer
 
Six secrets-to-closing-sale
Six secrets-to-closing-saleSix secrets-to-closing-sale
Six secrets-to-closing-sale
 
How Real-time Analysis turns Big Medical Data into Precision Medicine
How Real-time Analysis turns Big Medical Data into Precision MedicineHow Real-time Analysis turns Big Medical Data into Precision Medicine
How Real-time Analysis turns Big Medical Data into Precision Medicine
 
Anaesthetic management of valvular heart disease for non cardiac surgery
Anaesthetic management of valvular heart disease for non cardiac surgeryAnaesthetic management of valvular heart disease for non cardiac surgery
Anaesthetic management of valvular heart disease for non cardiac surgery
 
What Your Employees Don't Know About Healthcare [Infographic]
What Your Employees Don't Know About Healthcare [Infographic]What Your Employees Don't Know About Healthcare [Infographic]
What Your Employees Don't Know About Healthcare [Infographic]
 
Elsevier Medical Graph – mit Machine Learning zu Precision Medicine
Elsevier Medical Graph – mit Machine Learning zu Precision MedicineElsevier Medical Graph – mit Machine Learning zu Precision Medicine
Elsevier Medical Graph – mit Machine Learning zu Precision Medicine
 
How fit is your capital allocation strategy?
How fit is your capital allocation strategy? How fit is your capital allocation strategy?
How fit is your capital allocation strategy?
 
Genomic Medicine: Personalized Care for Just Pennies
Genomic Medicine: Personalized Care for Just PenniesGenomic Medicine: Personalized Care for Just Pennies
Genomic Medicine: Personalized Care for Just Pennies
 
Precision Medicine World Conference 2017
Precision Medicine World Conference 2017Precision Medicine World Conference 2017
Precision Medicine World Conference 2017
 
C-Change Cancer Big Data, NCI Genomic Data Commons, Cloud Pilots
C-Change Cancer Big Data, NCI Genomic Data Commons, Cloud PilotsC-Change Cancer Big Data, NCI Genomic Data Commons, Cloud Pilots
C-Change Cancer Big Data, NCI Genomic Data Commons, Cloud Pilots
 
Precision Medicine: Opportunities and Challenges for Clinical Trials
Precision Medicine: Opportunities and Challenges for Clinical TrialsPrecision Medicine: Opportunities and Challenges for Clinical Trials
Precision Medicine: Opportunities and Challenges for Clinical Trials
 

Similaire à Turning the tide on cancer drug costs

The role of health technology assessment bodies in the value of cancer care i...
The role of health technology assessment bodies in the value of cancer care i...The role of health technology assessment bodies in the value of cancer care i...
The role of health technology assessment bodies in the value of cancer care i...Francois MAIGNEN
 
Rationale and Procedure for Oncology Pricing and Reimbursement in England Tow...
Rationale and Procedure for Oncology Pricing and Reimbursement in England Tow...Rationale and Procedure for Oncology Pricing and Reimbursement in England Tow...
Rationale and Procedure for Oncology Pricing and Reimbursement in England Tow...Office of Health Economics
 
Advocacy and the cancer patient viewpoint
Advocacy and the cancer patient viewpointAdvocacy and the cancer patient viewpoint
Advocacy and the cancer patient viewpointIMSHealthRWES
 
{79718629-3ee8-46c6-97ac-40acfe150694}_4549_Aligning_Cost_with_Value_Whitepaper
{79718629-3ee8-46c6-97ac-40acfe150694}_4549_Aligning_Cost_with_Value_Whitepaper{79718629-3ee8-46c6-97ac-40acfe150694}_4549_Aligning_Cost_with_Value_Whitepaper
{79718629-3ee8-46c6-97ac-40acfe150694}_4549_Aligning_Cost_with_Value_WhitepaperUlrich Neumann, FRSA
 
Cancer Clinical Trials_ USA Scenario and Study Designs.pdf
Cancer Clinical Trials_ USA Scenario and Study Designs.pdfCancer Clinical Trials_ USA Scenario and Study Designs.pdf
Cancer Clinical Trials_ USA Scenario and Study Designs.pdfProRelix Research
 
Precision Medicine in Oncology Informatics
Precision Medicine in Oncology InformaticsPrecision Medicine in Oncology Informatics
Precision Medicine in Oncology InformaticsWarren Kibbe
 
Lexington Health Practice 'The future of Market Access' Interactive Pamphlet
Lexington Health Practice 'The future of Market Access' Interactive PamphletLexington Health Practice 'The future of Market Access' Interactive Pamphlet
Lexington Health Practice 'The future of Market Access' Interactive PamphletEmily Stevenson
 
The value partnership between NHS, industry and other providers
The value partnership between NHS, industry and other providersThe value partnership between NHS, industry and other providers
The value partnership between NHS, industry and other providersGS1 UK
 
Clinical oncology-can-observational-research-impact-clinical-decision-making
Clinical oncology-can-observational-research-impact-clinical-decision-makingClinical oncology-can-observational-research-impact-clinical-decision-making
Clinical oncology-can-observational-research-impact-clinical-decision-makingsmithjgrace
 
World Cancer Day
World Cancer DayWorld Cancer Day
World Cancer DayEMMAIntl
 

Similaire à Turning the tide on cancer drug costs (20)

The value of generics and biosimilar drugs
The value of generics and biosimilar drugsThe value of generics and biosimilar drugs
The value of generics and biosimilar drugs
 
The role of health technology assessment bodies in the value of cancer care i...
The role of health technology assessment bodies in the value of cancer care i...The role of health technology assessment bodies in the value of cancer care i...
The role of health technology assessment bodies in the value of cancer care i...
 
Directed Project
Directed ProjectDirected Project
Directed Project
 
Cancer 2014: Why do we need a focus on value?
Cancer 2014: Why do we need a focus on value?Cancer 2014: Why do we need a focus on value?
Cancer 2014: Why do we need a focus on value?
 
Origin of healthcare funding models
Origin of healthcare funding modelsOrigin of healthcare funding models
Origin of healthcare funding models
 
Ispor 2019 poster - Patricia Cubi-Molla
Ispor 2019 poster - Patricia Cubi-MollaIspor 2019 poster - Patricia Cubi-Molla
Ispor 2019 poster - Patricia Cubi-Molla
 
Rationale and Procedure for Oncology Pricing and Reimbursement in England Tow...
Rationale and Procedure for Oncology Pricing and Reimbursement in England Tow...Rationale and Procedure for Oncology Pricing and Reimbursement in England Tow...
Rationale and Procedure for Oncology Pricing and Reimbursement in England Tow...
 
Cancereconomics
CancereconomicsCancereconomics
Cancereconomics
 
Advocacy and the cancer patient viewpoint
Advocacy and the cancer patient viewpointAdvocacy and the cancer patient viewpoint
Advocacy and the cancer patient viewpoint
 
1410 prof james raftery nhc2015
1410 prof james raftery nhc20151410 prof james raftery nhc2015
1410 prof james raftery nhc2015
 
{79718629-3ee8-46c6-97ac-40acfe150694}_4549_Aligning_Cost_with_Value_Whitepaper
{79718629-3ee8-46c6-97ac-40acfe150694}_4549_Aligning_Cost_with_Value_Whitepaper{79718629-3ee8-46c6-97ac-40acfe150694}_4549_Aligning_Cost_with_Value_Whitepaper
{79718629-3ee8-46c6-97ac-40acfe150694}_4549_Aligning_Cost_with_Value_Whitepaper
 
Precision Medicine in Oncology
Precision Medicine in OncologyPrecision Medicine in Oncology
Precision Medicine in Oncology
 
Cancer Clinical Trials_ USA Scenario and Study Designs.pdf
Cancer Clinical Trials_ USA Scenario and Study Designs.pdfCancer Clinical Trials_ USA Scenario and Study Designs.pdf
Cancer Clinical Trials_ USA Scenario and Study Designs.pdf
 
Pr. Peivand Pirouzi - Calcium channel blocker treatments and cancer risk 2015...
Pr. Peivand Pirouzi - Calcium channel blocker treatments and cancer risk 2015...Pr. Peivand Pirouzi - Calcium channel blocker treatments and cancer risk 2015...
Pr. Peivand Pirouzi - Calcium channel blocker treatments and cancer risk 2015...
 
The Financial Burden.pdf
The Financial Burden.pdfThe Financial Burden.pdf
The Financial Burden.pdf
 
Precision Medicine in Oncology Informatics
Precision Medicine in Oncology InformaticsPrecision Medicine in Oncology Informatics
Precision Medicine in Oncology Informatics
 
Lexington Health Practice 'The future of Market Access' Interactive Pamphlet
Lexington Health Practice 'The future of Market Access' Interactive PamphletLexington Health Practice 'The future of Market Access' Interactive Pamphlet
Lexington Health Practice 'The future of Market Access' Interactive Pamphlet
 
The value partnership between NHS, industry and other providers
The value partnership between NHS, industry and other providersThe value partnership between NHS, industry and other providers
The value partnership between NHS, industry and other providers
 
Clinical oncology-can-observational-research-impact-clinical-decision-making
Clinical oncology-can-observational-research-impact-clinical-decision-makingClinical oncology-can-observational-research-impact-clinical-decision-making
Clinical oncology-can-observational-research-impact-clinical-decision-making
 
World Cancer Day
World Cancer DayWorld Cancer Day
World Cancer Day
 

Plus de EY

EY Price Point Q3 2022
EY Price Point Q3 2022EY Price Point Q3 2022
EY Price Point Q3 2022EY
 
Quarterly analyst themes of oil and gas earnings, Q1 2022
Quarterly analyst themes of oil and gas earnings, Q1 2022Quarterly analyst themes of oil and gas earnings, Q1 2022
Quarterly analyst themes of oil and gas earnings, Q1 2022EY
 
EY Price Point: global oil and gas market outlook, Q2 | April 2022
EY Price Point: global oil and gas market outlook, Q2 | April 2022EY Price Point: global oil and gas market outlook, Q2 | April 2022
EY Price Point: global oil and gas market outlook, Q2 | April 2022EY
 
EY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlookEY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlookEY
 
EY Price Point: global oil and gas market outlook, Q2 April 2021
EY Price Point: global oil and gas market outlook, Q2 April 2021EY Price Point: global oil and gas market outlook, Q2 April 2021
EY Price Point: global oil and gas market outlook, Q2 April 2021EY
 
Tax Alerte - Principales dispositions loi de finances 2021
Tax Alerte - Principales dispositions loi de finances 2021Tax Alerte - Principales dispositions loi de finances 2021
Tax Alerte - Principales dispositions loi de finances 2021EY
 
EY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlookEY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlookEY
 
Tax Alerte - prix de transfert - PLF 2021
Tax Alerte - prix de transfert - PLF 2021Tax Alerte - prix de transfert - PLF 2021
Tax Alerte - prix de transfert - PLF 2021EY
 
EY Price Point: global oil and gas market outlook (Q4, October 2020)
EY Price Point: global oil and gas market outlook (Q4, October 2020)EY Price Point: global oil and gas market outlook (Q4, October 2020)
EY Price Point: global oil and gas market outlook (Q4, October 2020)EY
 
EY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlookEY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlookEY
 
Zahl der Gewinnwarnungen steigt auf Rekordniveau
Zahl der Gewinnwarnungen steigt auf RekordniveauZahl der Gewinnwarnungen steigt auf Rekordniveau
Zahl der Gewinnwarnungen steigt auf RekordniveauEY
 
Versicherer rechnen mit weniger Neugeschäft
Versicherer rechnen mit weniger NeugeschäftVersicherer rechnen mit weniger Neugeschäft
Versicherer rechnen mit weniger NeugeschäftEY
 
Liquidity for advanced manufacturing and automotive sectors in the face of Co...
Liquidity for advanced manufacturing and automotive sectors in the face of Co...Liquidity for advanced manufacturing and automotive sectors in the face of Co...
Liquidity for advanced manufacturing and automotive sectors in the face of Co...EY
 
IBOR transition: Opportunities and challenges for the asset management industry
IBOR transition: Opportunities and challenges for the asset management industryIBOR transition: Opportunities and challenges for the asset management industry
IBOR transition: Opportunities and challenges for the asset management industryEY
 
Fusionen und Übernahmen dürften nach der Krise zunehmen
Fusionen und Übernahmen dürften nach der Krise zunehmenFusionen und Übernahmen dürften nach der Krise zunehmen
Fusionen und Übernahmen dürften nach der Krise zunehmenEY
 
Start-ups: Absturz nach dem Boom?
Start-ups: Absturz nach dem Boom?Start-ups: Absturz nach dem Boom?
Start-ups: Absturz nach dem Boom?EY
 
EY Price Point: global oil and gas market outlook, Q2, April 2020
EY Price Point: global oil and gas market outlook, Q2, April 2020EY Price Point: global oil and gas market outlook, Q2, April 2020
EY Price Point: global oil and gas market outlook, Q2, April 2020EY
 
Riding the crest of digital health in APAC
Riding the crest of digital health in APACRiding the crest of digital health in APAC
Riding the crest of digital health in APACEY
 
EY Chemical Market Outlook - February 2020
EY Chemical Market Outlook - February 2020EY Chemical Market Outlook - February 2020
EY Chemical Market Outlook - February 2020EY
 
Jobmotor Mittelstand gerät ins Stocken
Jobmotor Mittelstand gerät ins Stocken Jobmotor Mittelstand gerät ins Stocken
Jobmotor Mittelstand gerät ins Stocken EY
 

Plus de EY (20)

EY Price Point Q3 2022
EY Price Point Q3 2022EY Price Point Q3 2022
EY Price Point Q3 2022
 
Quarterly analyst themes of oil and gas earnings, Q1 2022
Quarterly analyst themes of oil and gas earnings, Q1 2022Quarterly analyst themes of oil and gas earnings, Q1 2022
Quarterly analyst themes of oil and gas earnings, Q1 2022
 
EY Price Point: global oil and gas market outlook, Q2 | April 2022
EY Price Point: global oil and gas market outlook, Q2 | April 2022EY Price Point: global oil and gas market outlook, Q2 | April 2022
EY Price Point: global oil and gas market outlook, Q2 | April 2022
 
EY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlookEY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlook
 
EY Price Point: global oil and gas market outlook, Q2 April 2021
EY Price Point: global oil and gas market outlook, Q2 April 2021EY Price Point: global oil and gas market outlook, Q2 April 2021
EY Price Point: global oil and gas market outlook, Q2 April 2021
 
Tax Alerte - Principales dispositions loi de finances 2021
Tax Alerte - Principales dispositions loi de finances 2021Tax Alerte - Principales dispositions loi de finances 2021
Tax Alerte - Principales dispositions loi de finances 2021
 
EY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlookEY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlook
 
Tax Alerte - prix de transfert - PLF 2021
Tax Alerte - prix de transfert - PLF 2021Tax Alerte - prix de transfert - PLF 2021
Tax Alerte - prix de transfert - PLF 2021
 
EY Price Point: global oil and gas market outlook (Q4, October 2020)
EY Price Point: global oil and gas market outlook (Q4, October 2020)EY Price Point: global oil and gas market outlook (Q4, October 2020)
EY Price Point: global oil and gas market outlook (Q4, October 2020)
 
EY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlookEY Price Point: global oil and gas market outlook
EY Price Point: global oil and gas market outlook
 
Zahl der Gewinnwarnungen steigt auf Rekordniveau
Zahl der Gewinnwarnungen steigt auf RekordniveauZahl der Gewinnwarnungen steigt auf Rekordniveau
Zahl der Gewinnwarnungen steigt auf Rekordniveau
 
Versicherer rechnen mit weniger Neugeschäft
Versicherer rechnen mit weniger NeugeschäftVersicherer rechnen mit weniger Neugeschäft
Versicherer rechnen mit weniger Neugeschäft
 
Liquidity for advanced manufacturing and automotive sectors in the face of Co...
Liquidity for advanced manufacturing and automotive sectors in the face of Co...Liquidity for advanced manufacturing and automotive sectors in the face of Co...
Liquidity for advanced manufacturing and automotive sectors in the face of Co...
 
IBOR transition: Opportunities and challenges for the asset management industry
IBOR transition: Opportunities and challenges for the asset management industryIBOR transition: Opportunities and challenges for the asset management industry
IBOR transition: Opportunities and challenges for the asset management industry
 
Fusionen und Übernahmen dürften nach der Krise zunehmen
Fusionen und Übernahmen dürften nach der Krise zunehmenFusionen und Übernahmen dürften nach der Krise zunehmen
Fusionen und Übernahmen dürften nach der Krise zunehmen
 
Start-ups: Absturz nach dem Boom?
Start-ups: Absturz nach dem Boom?Start-ups: Absturz nach dem Boom?
Start-ups: Absturz nach dem Boom?
 
EY Price Point: global oil and gas market outlook, Q2, April 2020
EY Price Point: global oil and gas market outlook, Q2, April 2020EY Price Point: global oil and gas market outlook, Q2, April 2020
EY Price Point: global oil and gas market outlook, Q2, April 2020
 
Riding the crest of digital health in APAC
Riding the crest of digital health in APACRiding the crest of digital health in APAC
Riding the crest of digital health in APAC
 
EY Chemical Market Outlook - February 2020
EY Chemical Market Outlook - February 2020EY Chemical Market Outlook - February 2020
EY Chemical Market Outlook - February 2020
 
Jobmotor Mittelstand gerät ins Stocken
Jobmotor Mittelstand gerät ins Stocken Jobmotor Mittelstand gerät ins Stocken
Jobmotor Mittelstand gerät ins Stocken
 

Dernier

Storage_of _Bariquin_Components_in_Storage_Boxes.pptx
Storage_of _Bariquin_Components_in_Storage_Boxes.pptxStorage_of _Bariquin_Components_in_Storage_Boxes.pptx
Storage_of _Bariquin_Components_in_Storage_Boxes.pptxBariquins
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxdrtabassum4
 
Valle Egypt Illustrates Consequences of Financial Elder Abuse
Valle Egypt Illustrates Consequences of Financial Elder AbuseValle Egypt Illustrates Consequences of Financial Elder Abuse
Valle Egypt Illustrates Consequences of Financial Elder AbuseKristin Hetzer
 
Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\DanielOliver74
 
Importance of Diet on Dental Health.docx
Importance of Diet on Dental Health.docxImportance of Diet on Dental Health.docx
Importance of Diet on Dental Health.docxSachin Mittal
 
Improve Patient Care with Medical Record Abstraction
Improve Patient Care with Medical Record AbstractionImprove Patient Care with Medical Record Abstraction
Improve Patient Care with Medical Record AbstractionCardiac Registry Support
 
Enhancing-Patient-Centric-Clinical-Trials.pdf
Enhancing-Patient-Centric-Clinical-Trials.pdfEnhancing-Patient-Centric-Clinical-Trials.pdf
Enhancing-Patient-Centric-Clinical-Trials.pdfgajendrasinh1303
 
Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur
Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur
Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur aunty1x1
 
Mental Health Startup Pitch Deck Presentation
Mental Health Startup Pitch Deck PresentationMental Health Startup Pitch Deck Presentation
Mental Health Startup Pitch Deck PresentationStartupSprouts.in
 
Virtual Health Platforms_ Revolutionizing Patient Care.pdf
Virtual Health Platforms_ Revolutionizing Patient Care.pdfVirtual Health Platforms_ Revolutionizing Patient Care.pdf
Virtual Health Platforms_ Revolutionizing Patient Care.pdfsmartcare
 
The Best Foot and Ankle Center of Arizona
The Best Foot and Ankle Center of ArizonaThe Best Foot and Ankle Center of Arizona
The Best Foot and Ankle Center of Arizonajackjohn60
 
Unlocking the Benefits of Cognitive Behavioural Therapy (CBT) with Renewed Edge
Unlocking the Benefits of Cognitive Behavioural Therapy (CBT) with Renewed EdgeUnlocking the Benefits of Cognitive Behavioural Therapy (CBT) with Renewed Edge
Unlocking the Benefits of Cognitive Behavioural Therapy (CBT) with Renewed Edgerenewed edge
 
Benefits of Dentulu's Salivary Testing.pptx
Benefits of Dentulu's Salivary Testing.pptxBenefits of Dentulu's Salivary Testing.pptx
Benefits of Dentulu's Salivary Testing.pptxDentulu Inc
 
#cALL# #gIRLS# In Chhattisgarh ꧁❤8901183002❤꧂#cALL# #gIRLS# Service In Chhatt...
#cALL# #gIRLS# In Chhattisgarh ꧁❤8901183002❤꧂#cALL# #gIRLS# Service In Chhatt...#cALL# #gIRLS# In Chhattisgarh ꧁❤8901183002❤꧂#cALL# #gIRLS# Service In Chhatt...
#cALL# #gIRLS# In Chhattisgarh ꧁❤8901183002❤꧂#cALL# #gIRLS# Service In Chhatt...aunty1x1
 
PhRMA Vaccines Deck_05-15_2024_FINAL.pptx
PhRMA Vaccines Deck_05-15_2024_FINAL.pptxPhRMA Vaccines Deck_05-15_2024_FINAL.pptx
PhRMA Vaccines Deck_05-15_2024_FINAL.pptxBlake100757
 
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...aunty1x1
 
Thoracic Vertebrae: Anatomy, Function, and Common Disorders | The Lifescience...
Thoracic Vertebrae: Anatomy, Function, and Common Disorders | The Lifescience...Thoracic Vertebrae: Anatomy, Function, and Common Disorders | The Lifescience...
Thoracic Vertebrae: Anatomy, Function, and Common Disorders | The Lifescience...The Lifesciences Magazine
 
ASSISTING WITH THE USE OF URINAL BY ANUSHRI SRIVASTAVA.pptx
ASSISTING WITH THE USE OF URINAL BY ANUSHRI SRIVASTAVA.pptxASSISTING WITH THE USE OF URINAL BY ANUSHRI SRIVASTAVA.pptx
ASSISTING WITH THE USE OF URINAL BY ANUSHRI SRIVASTAVA.pptxAnushriSrivastav
 
Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...
Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...
Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...GQ Research
 
Integrated Mother and Neonate Childwood Illness Health Care
Integrated Mother and Neonate Childwood Illness  Health CareIntegrated Mother and Neonate Childwood Illness  Health Care
Integrated Mother and Neonate Childwood Illness Health CareASKatoch1
 

Dernier (20)

Storage_of _Bariquin_Components_in_Storage_Boxes.pptx
Storage_of _Bariquin_Components_in_Storage_Boxes.pptxStorage_of _Bariquin_Components_in_Storage_Boxes.pptx
Storage_of _Bariquin_Components_in_Storage_Boxes.pptx
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
 
Valle Egypt Illustrates Consequences of Financial Elder Abuse
Valle Egypt Illustrates Consequences of Financial Elder AbuseValle Egypt Illustrates Consequences of Financial Elder Abuse
Valle Egypt Illustrates Consequences of Financial Elder Abuse
 
Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
 
Importance of Diet on Dental Health.docx
Importance of Diet on Dental Health.docxImportance of Diet on Dental Health.docx
Importance of Diet on Dental Health.docx
 
Improve Patient Care with Medical Record Abstraction
Improve Patient Care with Medical Record AbstractionImprove Patient Care with Medical Record Abstraction
Improve Patient Care with Medical Record Abstraction
 
Enhancing-Patient-Centric-Clinical-Trials.pdf
Enhancing-Patient-Centric-Clinical-Trials.pdfEnhancing-Patient-Centric-Clinical-Trials.pdf
Enhancing-Patient-Centric-Clinical-Trials.pdf
 
Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur
Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur
Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur
 
Mental Health Startup Pitch Deck Presentation
Mental Health Startup Pitch Deck PresentationMental Health Startup Pitch Deck Presentation
Mental Health Startup Pitch Deck Presentation
 
Virtual Health Platforms_ Revolutionizing Patient Care.pdf
Virtual Health Platforms_ Revolutionizing Patient Care.pdfVirtual Health Platforms_ Revolutionizing Patient Care.pdf
Virtual Health Platforms_ Revolutionizing Patient Care.pdf
 
The Best Foot and Ankle Center of Arizona
The Best Foot and Ankle Center of ArizonaThe Best Foot and Ankle Center of Arizona
The Best Foot and Ankle Center of Arizona
 
Unlocking the Benefits of Cognitive Behavioural Therapy (CBT) with Renewed Edge
Unlocking the Benefits of Cognitive Behavioural Therapy (CBT) with Renewed EdgeUnlocking the Benefits of Cognitive Behavioural Therapy (CBT) with Renewed Edge
Unlocking the Benefits of Cognitive Behavioural Therapy (CBT) with Renewed Edge
 
Benefits of Dentulu's Salivary Testing.pptx
Benefits of Dentulu's Salivary Testing.pptxBenefits of Dentulu's Salivary Testing.pptx
Benefits of Dentulu's Salivary Testing.pptx
 
#cALL# #gIRLS# In Chhattisgarh ꧁❤8901183002❤꧂#cALL# #gIRLS# Service In Chhatt...
#cALL# #gIRLS# In Chhattisgarh ꧁❤8901183002❤꧂#cALL# #gIRLS# Service In Chhatt...#cALL# #gIRLS# In Chhattisgarh ꧁❤8901183002❤꧂#cALL# #gIRLS# Service In Chhatt...
#cALL# #gIRLS# In Chhattisgarh ꧁❤8901183002❤꧂#cALL# #gIRLS# Service In Chhatt...
 
PhRMA Vaccines Deck_05-15_2024_FINAL.pptx
PhRMA Vaccines Deck_05-15_2024_FINAL.pptxPhRMA Vaccines Deck_05-15_2024_FINAL.pptx
PhRMA Vaccines Deck_05-15_2024_FINAL.pptx
 
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...
 
Thoracic Vertebrae: Anatomy, Function, and Common Disorders | The Lifescience...
Thoracic Vertebrae: Anatomy, Function, and Common Disorders | The Lifescience...Thoracic Vertebrae: Anatomy, Function, and Common Disorders | The Lifescience...
Thoracic Vertebrae: Anatomy, Function, and Common Disorders | The Lifescience...
 
ASSISTING WITH THE USE OF URINAL BY ANUSHRI SRIVASTAVA.pptx
ASSISTING WITH THE USE OF URINAL BY ANUSHRI SRIVASTAVA.pptxASSISTING WITH THE USE OF URINAL BY ANUSHRI SRIVASTAVA.pptx
ASSISTING WITH THE USE OF URINAL BY ANUSHRI SRIVASTAVA.pptx
 
Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...
Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...
Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...
 
Integrated Mother and Neonate Childwood Illness Health Care
Integrated Mother and Neonate Childwood Illness  Health CareIntegrated Mother and Neonate Childwood Illness  Health Care
Integrated Mother and Neonate Childwood Illness Health Care
 

Turning the tide on cancer drug costs

  • 1. Turning the tide on cancer drug costs The increase in the median monthly cost of cancer drugs in the US since 19902 ©2015EYGMLimited.AllRightsReserved.EYGno.FN0236.EDNone 1 A rising tide of new cancer drugs helps patients. These contracts are complex to build, but can provide a strong foundation for patient access. To hold back the tide of oncology drug costs, payers …3 ... experiment with new models US payers test indication-specific pricing, taking advantage of four new drug value tools. Since 2006, NICE has issued negative recommendations for of the cancer drugs reviewed.3 ... limit patient access Innovative risk-sharing agreements are another way to turn the tide.4 of the contracts are for cancer drugs.4 65%The number of risk-sharing contracts created in the UK and Italy since 2006 90 Sources: 1 U.S. Food & Drug Administration, Memorial Sloan Kettering Cancer Center, Decision Resources. 2 Peter Bach, Memorial Sloan Kettering Cancer Center, Center for Health Policy and Outcomes, "Price and Value of Cancer Drug," 2015. 3 EY, National Institute for Health and Care Excellence (NICE). 4 Van de Vooren, et al., “Market-access agreements for anti-cancer drugs,” J R Soc Med (108): 166–170, 2015. Since 1990, new cancer drugs have been approved in the US. 117 50Another could reach the market by 2020.1 $41% >700% 2 This wave of innovation could drown payers.